

13th International Conference
CHRONIC MYELOID LEUKEMIA
Biology and therapy

Chairs: J.M. Goldman (London), J. Cortes (Houston), T.P. Hughes (Adelaide)

Co-Organizers: T. Holyoake (Glasgow), F.-X. Mahon (Bordeaux),
D. Perrotti (Colombus), J. Radich (Seattle)

22-25 September, 2011
Estoril, Portugal

Deadline for abstracts:
June 30, 2011



Main Topics:

• **Clinical**

- When to use 2nd generation tyrosine kinase inhibitors
- How should we best monitor responding patients?
- Are we satisfied with complete cytogenetic response?
- How to avoid or overcome TKI resistance
- A renaissance for interferon-alfa?
- The place of allogeneic stem cell transplantation
- CML and pregnancy
- Future trends in therapy

• **Biological**

- BCR-ABL1 signal transduction
- Mechanisms of disease progression
- Molecular basis of stem cell renewal - beta catenin, notch, BMI-1
- Genomic instability, kinase domain mutations and progression to advanced phase
- Immunological targets including WT-1 and IL1-RAP

To register and for further information
www.esh.org

Or contact
ghyslaine.lebougault@univ-paris-diderot.fr
or caroline.lamy@univ-paris-diderot.fr